{"id":"W4403320599","doi":"10.1212/nxi.0000000000200321","title":"Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis","year":2024,"lang":"en","type":"article","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"UCB Pharma; Sanofi Genzyme; EMD Serono; Genentech; Biogen; Celgene; Alexion Pharmaceuticals; Shionogi; Sanofi; Teva Pharmaceutical Industries; Bristol-Myers Squibb; Eli Lilly and Company","keywords":"Dosing; Natalizumab; Multiple sclerosis; Pharmacodynamics; Pharmacokinetics; Medicine; Relapsing remitting; Pharmacology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001712654,0.0003012053,0.0006904287,0.0001938832,0.0001287898,0.0005853048,0.0004178159,0.000528105,0.00104346],"category_scores_gemma":[0.00269208,0.000290613,0.0005918939,0.0001849612,0.0002792993,0.0004485274,0.0001455636,0.00115096,0.0003132083],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006013956,"about_ca_system_score_gemma":0.0004379295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004854343,"about_ca_topic_score_gemma":0.0006179655,"domain_scores_codex":[0.9991609,0.0004322444,0.00003965959,0.0001513022,0.0001463001,0.00006962027],"domain_scores_gemma":[0.998866,0.0003335263,0.0004880143,0.00009696178,0.00005782238,0.0001577755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5325007,0.01114968,0.07943221,0.0003881715,0.002146977,0.0001967221,0.0005103289,0.011461,0.1524024,0.0002997295,0.001334972,0.208177],"study_design_scores_gemma":[0.05374217,0.4610999,0.3963323,0.00007210301,0.002264132,0.001131399,0.0001585276,0.03312705,0.04590778,0.0008028137,0.005188323,0.0001736434],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986234,0.0005159294,0.0003873227,0.00004681426,0.00001015741,0.00006722411,0.0001227569,0.0000223009,0.0002041797],"genre_scores_gemma":[0.9987838,0.0001555506,0.000511434,0.00004926846,0.00001193881,0.0000873623,0.0001282141,0.000007068586,0.0002655165],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001712654,"threshold_uncertainty_score":0.009057462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0320156708101307,"score_gpt":0.2740794635867067,"score_spread":0.242063792776576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}